The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
NU HLDGS LTD | ORD SHS CL A | G6683N103 | 18,457,848 | 1,431,951 | SH | SOLE | 1,431,951 | 0 | 0 | ||
AKERO THERAPEUTICS INC | COM | 00973Y108 | 9,943,498 | 423,849 | SH | SOLE | 423,849 | 0 | 0 | ||
89BIO INC | COM | 282559103 | 5,800,297 | 724,132 | SH | SOLE | 724,132 | 0 | 0 | ||
GE AEROSPACE | COM NEW | 369604301 | 10,982,125 | 69,083 | SH | SOLE | 69,083 | 0 | 0 | ||
ISHARES TR | CORE S&P500 ETF | 464287200 | 30,835,316 | 56,348 | SH | SOLE | 56,348 | 0 | 0 | ||
MADRIGAL PHARMACEUTICALS INC | COM | 558868105 | 12,811,717 | 45,730 | SH | SOLE | 45,730 | 0 | 0 |